Hanmi Science Co.,Ltd
Financials
Valuation Metrics
Hanmi Science Co.,Ltd's Market Cap is ₩4.0T. At end of 2025 it was ₩2.5T. Ranked #131 of 2,419 in KR market (top 5%), #114 of 781 on KOSPI (top 15%), #2 of 95 in Health Care Equipment & Services (top 2%) by Market Cap.
Investment Metrics(as of 2026-10-07)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 3.97T KRW | KR#131/2,419 Sec#2/95 |
| Revenue | 1.41T KRW | KR#330/2,419 Sec#1/95 |
| Net Income | 150.89B KRW | KR#186/2,419 Sec#1/95 |
| Total Assets | 1.53T KRW | KR#369/2,419 Sec#3/95 |
| Net Assets | 1.06T KRW | KR#282/2,419 Sec#2/95 |
| Employees | 453 | KR#542/2,419 Sec#12/95 |
| Value | ||
| P/E | 26.33x | KR#1,257/2,419 Sec#41/95 |
| P/B | 3.75x | KR#2,159/2,419 Sec#79/95 |
| PEG | 0.16x | KR#505/2,419 Sec#23/95 |
| P/S | 2.82x | KR#1,951/2,419 Sec#60/95 |
| EV/EBITDA | 23.91x | KR#1,084/2,419 Sec#35/95 |
| Profitability | ||
| ROE | 14.22% | KR#357/2,419 Sec#11/95 |
| ROA | 9.85% | KR#282/2,419 Sec#14/95 |
| Op. Margin | 12.06% | KR#420/2,419 Sec#25/95 |
| Revenue Growth | 6.30% | KR#1,118/2,419 Sec#63/95 |
| Earnings Growth | 165.36% | KR#281/2,419 Sec#16/95 |
| Financial Health | ||
| Debt Ratio | 44.44% | KR#874/2,419 Sec#48/95 |
| Total Debt | 182.72B KRW | KR#538/2,419 Sec#6/95 |
| Cash | 98.28B KRW | KR#477/2,419 Sec#5/95 |
| Current Ratio | 0.90x | KR#1,833/2,419 Sec#82/95 |
| Net Debt/EBITDA | 0.50x | KR#670/2,419 Sec#27/95 |
| Dividend | ||
| Div. Yield | 0.52% | KR#1,242/2,419 Sec#38/95 |
| Div. Growth | 0.00% | KR—/2,419 Sec—/95 |
| Performance | ||
| 1Y Return | 52.49% | KR#257/2,419 Sec#6/95 |
| 1M Return | 7.20% | KR#666/2,419 Sec#40/95 |
| From 52W High | -4.75% | KR#35/2,419 Sec#2/95 |
| 1Y MDD | -48.52% | KR#936/2,419 Sec#34/95 |
| Trading | ||
| Volume | 108,960 shares | KR#775/2,419 Sec#28/95 |
| Trading Value | 6.29B KRW | KR#343/2,419 Sec#7/95 |
| Foreign Own. | 1.19% | KR#1,952/2,419 Sec#70/95 |
| Per Share | ||
| EPS | 2,206 KRW | KR#423/2,419 Sec#9/95 |
| BPS | 15,514 KRW | KR#683/2,419 Sec#9/95 |
Company Info
Hanmi Science, established in 1973, received approval for conversion to a holding company in 2011. In 2022, it merged with Hanmi Healthcare, adding a healthcare business division and transforming into an operating holding company. It generates profit through equity gains from subsidiaries, patent and trademark royalty income, healthcare business, and affiliate management, holding 8 subsidiaries including Hanmi Pharmaceutical. As an operating holding company, it is dedicated to discovering new growth engines, sharing new drug development risks, and establishing mid-to-long-term visions to lead the rapidly changing global healthcare market. Hanmi Science is headquartered in Hwaseong-si, Gyeonggi-do.